Clinical trials: Localized Cancer
Non Hematologic Cancers
Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies
This is a phase I, open-label, dose-escalation trial of defactinib (VS-6063), a focal adhesion kinase inhibitor, in Japanese patients with non-hematologic malignancies.
- Trial name
- NCT01943292
- Testing
- Defactinib
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Verastem, Inc.
Moderate or Severe Submental Fullness
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
- Trial name
- NCT01546142
- Testing
- Deoxycholic acid injection
- Where
- 35 sites in United States, Canada
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Neoplasms, Prostate
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
The purpose of this study is to examine the effect of dutasteride on the inhibition of low-risk, localized prostate cancer progression in men who would otherwise receive no active therapy (expectant management).
- Trial name
- NCT00363311
- Testing
- Dutasteride
- Where
- 82 sites in United States, Canada
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Esophageal Cancer, Adenocarcinoma of the Esophagus
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time.
- Conditions
- Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
- Trial name
- NCT00573131
- Testing
- OncoGel (Paclitaxel gel), cisplatin, 5-FU
- Where
- 20 sites in United States, Czechia and 2 more
- Volunteers
- 137 people
- Sponsor
- Boston Scientific Corporation
Platinum Resistant Ovarian Cancer
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase 2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo in subjects with…
- Trial name
- NCT02641639
- Testing
- Fosbretabulin tromethamine
- Where
- 40 sites in United States, Belgium and 1 more
- Volunteers
- 70 people
- Sponsor
- Mateon Therapeutics
Prostate Cancer
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
The primary purpose of this study was to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.
- Trial name
- ENACT (NCT02799745)
- Testing
- Enzalutamide, Active Surveillance
- Where
- 54 sites in United States, Canada
- Volunteers
- 227 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Liver Cancer
A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
This single-arm, open-label study assessed the efficacy and safety of Avastin (bevacizumab) treatment combined with transarterial chemoembolisation (TACE) in patients with localized unresectable liver cancer.
- Trial name
- NCT00576199
- Testing
- Bevacizumab, Transarterial chemoembolisation (TACE)
- Where
- 3 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer
An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate
The primary objective was to evaluate efficacy of a single dose of Liproca Depot in patients with localized prostate cancer. Primary efficacy variable was the proportion of patients showing PSA nadir.
- Trial name
- 2-HOF (NCT00913263)
- Testing
- 2-hydroxyflutamide (2-HOF) [Liproca Depot], 2-Hydroxyflutamide
- Where
- 2 sites in Finland
- Volunteers
- 24 people
- Sponsor
- Lidds AB
Brain Tumor
Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound
The purpose of this study is to evaluate the safety of BBB disruption using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent to increase the accumulation of doxorubicin in…
- Trial name
- NCT02343991
- Testing
- Transcranial ExABlate
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- InSightec
Liver Neoplasms
SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
The purpose of this study is to demonstrate the Sensitivity and Specificity of SonoVue®-enhanced ultrasound is superior to that of unenhanced ultrasound for the characterization of benign versus malignant FLLs using final…
- Trial name
- NCT00829413
- Testing
- SonoVue®
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- Bracco Diagnostics, Inc
Uterine Fibroids (Leiomyomas)
Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids
The Mirabilis High-Intensity Focused Ultrasound (HIFU) Treatment System delivers therapeutic focused ultrasound energy to the uterus under integrated ultrasound imaging guidance to offer non-invasive treatment for uterine…
- Trial name
- NCT01946178
- Testing
- Mirabilis High-Intensity Focused Ultrasound Treatment System
- Where
- 2 sites in Mexico
- Volunteers
- 73 people
- Sponsor
- Mirabilis Medica, Inc.
Metastatic Brain Tumor, Primary Brain Tumor
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical.
- Conditions
- Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
- Trial name
- LAANTERN (NCT02392078)
- Testing
- NeuroBlate System
- Where
- 26 sites in United States
- Volunteers
- 1,153 people
- Sponsor
- Monteris Medical
Neoplasms, Breast
Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer
This is an open-label, single-arm pilot study evaluating the antitumor activity and safety of niraparib as neoadjuvant therapy in participants with Human epidermal growth factor receptor 2 (HER2)-negative and breast cancer…
- Trial name
- NCT03329937
- Testing
- Niraparib
- Volunteers
- 21 people
- Sponsor
- Tesaro, Inc.
Liver Neoplasms, Adenoma
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
Medical records are reviewed to obtain information about the use of a MRI diagnostic imaging agent (contrast agent) called Primovist/Eovist in children older than 2 months and less than 18 years.
- Conditions
- Liver Neoplasms, Adenoma, Carcinoma, Liver Abscess
- Trial name
- NCT01043523
- Testing
- Gadoxetic Acid Disodium (Eovist, BAY86-4873)
- Where
- 9 sites in United States, Italy and 3 more
- Volunteers
- 52 people
- Sponsor
- Bayer
Moderate or Severe Submental Fullness
Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
- Trial name
- NCT01305577
- Testing
- Deoxycholic acid injection
- Where
- 30 sites in Belgium, France and 3 more
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Carcinoma, Renal Cell
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have…
- Trial name
- CheckMate 914 (NCT03138512)
- Testing
- nivolumab, ipilimumab
- Where
- 200 sites in United States, Argentina and 23 more
- Volunteers
- 1,641 people
- Sponsor
- Bristol-Myers Squibb
Pigmented Villonodular Synovitis, PVNS
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
This study, designed as a proof of concept study of MCS110 in pigmented villonodular synovitis, assessed the clinical response to MCS110 treatment in Pigmented Villonodular Synovitis (PVNS) patients, after a single or multiple…
- Conditions
- Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS
- Trial name
- NCT01643850
- Testing
- MCS110
- Where
- 8 sites in United States, Switzerland
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Localized T1-T2 Prostate Cancer
SpaceOAR System RWS in China
This study aims to evaluate the safety and performance of SpaceOAR System when it is used to create space between the rectum and prostate in men undergoing radiotherapy for localized T1-T2 prostate cancer in China via collecting…
- Trial name
- NCT05407714
- Testing
- SpaceOAR Treatment
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Prostate Cancer
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
- Trial name
- NCT02135445
- Testing
- TAK-385, Degarelix
- Where
- 25 sites in United States, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
This prospective observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in elderly patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
- Trial name
- NCT01535729
- Where
- Germany
- Volunteers
- 465 people
- Sponsor
- Hoffmann-La Roche